Infectious Diseases and HIV Conference

Infectious disease landscape is constantly changing with the changes in the therapeutic approach and the ever-increasing need to fight new and re-emerging pathogens.

In this session, recent innovations in infectious disease treatment- new therapies, challenges, and emerging research and practice directions-will be presented. This is truly a new discovery: new antimicrobial agents effective in controlling resistant pathogens.

This session will present recent breakthroughs in the development of antibiotics, new chemical structures discoveries, bacteriophage therapy, and combination drugs for the enhancement of already existing antibiotics.

Mechanisms of action of these new agents and future surveillance for monitoring resistance patterns will also be discussed. Antiviral therapies have dramatically altered the face of viral infections.

The present session will outline DAA development and how DAAs are crucially involved in managing chronic viral infections like HIV and hepatitis and COVID-19 more recently.

The participants will also be enlightened more about novel approaches to chronic viral infections due to therapeutic interventions by monoclonal antibodies, convalescent plasma, and RNA interference technology leading to the inhibition of viral replication.

As the world becomes open and fast in embracing immunotherapy as the next potent treatment mechanism against infectious diseases, harnessing one's body system takes center stage in combating infections.

In this session, new vaccine technologies such as mRNA vaccines and viral vector vaccines have been discussed in relation to recent breakthroughs into the prevention of infectious diseases.

Therapeutic vaccines for established infections are addressed here in the context of ongoing research and clinical trials. Infectious diseases prevail in low- and middle-income countries, and therefore effective and affordable treatments are badly needed.

This session will address some of the challenges in taking therapeutic advances into resource-limited settings, taking into account approaches for expanding treatment access, including public-private partnerships, as well as those under global health initiatives. Those participants will be taught the need for cooperation between governments, healthcare providers, and the pharmaceutical industry to redress these shortcomings.

Therapeutic Progression in Infectious Diseases in the Future the session would end with discussions on future therapeutic advances in infectious diseases, to include precision medicine approaches tailored for the patient profile. Emerging research in the role of the micro biome in the management of infectious disease and the development of personalized therapy would be emphasized.

Participants would leave with the message that this future of infectious disease therapeutics is one that would shape up in interdisciplinary collaboration and innovation.